Stock CYP CYNATA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cynata Therapeutics Limited

Equities

CYP

AU000000CYP7

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:05 2024-04-29 am EDT 		5-day change 1st Jan Change
0.21 AUD 0.00% Intraday chart for Cynata Therapeutics Limited 0.00% +68.00%
Apr. 08 Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial CI
Apr. 08 Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial MT

Valuation

Fiscal Period: June 2019 2020 2023 2024 2025 2026
Capitalization 1 126.8 71.45 22.45 37.72 - -
Enterprise Value (EV) 1 119.9 57.8 22.45 11.02 13.92 21.52
P/E ratio -14.7 x -17.5 x -1.27 x -4.04 x -6.56 x -12.4 x
Yield - - - - - -
Capitalization / Revenue 80.8 x 9.99 x - 16.4 x 41.9 x 5.24 x
EV / Revenue 76.4 x 8.08 x - 4.79 x 15.5 x 2.99 x
EV / EBITDA -14.6 x - - -1.19 x -1.7 x -4.89 x
EV / FCF -17.7 x - - -1.2 x -1.72 x -4.89 x
FCF Yield -5.64% - - -83.5% -58.2% -20.4%
Price to Book - - - 2.1 x 2.1 x -
Nbr of stocks (in thousands) 101,885 117,124 179,632 179,632 - -
Reference price 2 1.245 0.6100 0.1250 0.2100 0.2100 0.2100
Announcement Date 8/23/19 8/25/20 8/28/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Giugno 2019 2020 2023 2024 2025 2026
Net sales 1 1.569 7.154 - 2.3 0.9 7.2
EBITDA 1 -8.192 - - -9.3 -8.2 -4.4
EBIT 1 -8.472 -3.639 - -9.6 -8.5 -4.7
Operating Margin -539.94% -50.87% - -417.39% -944.44% -65.28%
Earnings before Tax (EBT) 1 -8.472 -3.639 - -9.4 -8.3 -4.6
Net income 1 -8.472 -3.639 -14.28 -9.4 -8.3 -4.6
Net margin -539.94% -50.87% - -408.7% -922.22% -63.89%
EPS 2 -0.0848 -0.0348 -0.0984 -0.0520 -0.0320 -0.0170
Free Cash Flow 1 -6.759 - - -9.2 -8.1 -4.4
FCF margin -430.76% - - -400% -900% -61.11%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/23/19 8/25/20 8/28/23 - - -
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2023 2024 2025 2026
Net Debt 1 - - - - - -
Net Cash position 1 6.98 13.6 - 26.7 23.8 16.2
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -6.76 - - -9.2 -8.1 -4.4
ROE (net income / shareholders' equity) -77.2% - - - - -
ROA (Net income/ Total Assets) -59.7% - - - - -
Assets 1 14.19 - - - - -
Book Value Per Share 2 - - - 0.1000 0.1000 -
Cash Flow per Share 2 - - - -0.0500 -0.0300 -0.0200
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 8/23/19 8/25/20 8/28/23 - - -
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CYNATA THERAPEUTICS LIMITED Stock Cynata Therapeutics Limited
+68.00% 24.6M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 95.28B
ARGENX SE Stock argenx SE
+1.46% 22.15B
BIONTECH SE Stock BioNTech SE
-16.67% 21.02B
GENMAB A/S Stock Genmab A/S
-8.58% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CYP Stock
  4. Financials Cynata Therapeutics Limited